Michiko Naka

Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase.

H. Hidaka, M. Naka, M. Saitoh, 1987, The Journal of biological chemistry.

Characterization of the myosin-binding subunit of smooth muscle myosin phosphatase.

T. Tanaka, D. Hartshorne, K. Hirano, 1994, The Journal of biological chemistry.

Calcium-regulated modulator protein interacting agents inhibit smooth muscle calcium-stimulated protein kinase and ATPase.

T. Tanaka, H. Hidaka, T. Yamaki, 1980, Molecular pharmacology.

Effect of novel specific myosin light chain kinase inhibitors on Ca2+-activated Mg2+-ATPase of chicken gizzard actomyosin.

H. Hidaka, T. Yamaki, M. Naka, 1979, Biochemical and biophysical research communications.

Human S100A11 exhibits differential steady-state RNA levels in various tissues and a distinct subcellular localization.

C. Heizmann, T. Tanaka, G. Davey, 1999, Biochemical and biophysical research communications.

Pharmacogenomics and therapeutic target validation in cerebral vasospasm.

Y. Nishimura, M. Naka, T. Tanaka, 2000, Journal of cardiovascular pharmacology.

Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysis

M. Naka, K. Maruyama, H. Amano, 2003, The Pharmacogenomics Journal.